329314-68-3

Usage

Uses

Used in Pharmaceutical Industry:
Benzonitrile, 2,4-difluoro-5-methyl(9CI) is used as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the development of new drugs, enhancing their efficacy and selectivity in treating various medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, Benzonitrile, 2,4-difluoro-5-methyl(9CI) serves as a key intermediate in the production of pesticides and other crop protection agents. Its ability to participate in various chemical reactions enables the creation of novel agrochemicals with improved performance and reduced environmental impact.
Used in Organic Synthesis:
Benzonitrile, 2,4-difluoro-5-methyl(9CI) is utilized as a versatile building block in organic synthesis. Its reactivity and compatibility with various chemical reactions make it an essential component in the synthesis of complex organic compounds, including specialty chemicals, dyes, and other industrial products.
Used in Research and Development:
As a member of the benzonitrile class, Benzonitrile, 2,4-difluoro-5-methyl(9CI) is employed in research and development for exploring new chemical reactions and pathways. Its unique properties and reactivity contribute to the advancement of chemical knowledge and the discovery of innovative applications in various industries.

InChI:InChI=1/C8H5F2N/c1-5-2-6(4-11)8(10)3-7(5)9/h2-3H,1H3

Upstream product

• 557-21-1 dicyanozinc 
• 333447-42-0 1,5-difluoro-2-iodo-4-methylbenzene 
• 557-21-1 zinc(II) cyanide 
• 452-76-6 2,4-difluorotoluene 
• 73963-98-1 zinc cyanide 
• 544-92-3 copper(I) cyanide 
• 159277-47-1 1-bromo-2,4-difluoro-5-methylbenzene 

Downstream Products

• 329314-63-8 2,4-difluoro-5-methylbenzylamine 
• 367954-99-2 2,4-Difluoro-5-methylbenzoic acid 
• 633327-10-3 2,4-difluoro-5-formylbenzonitrile 

Relevant academic research and scientific papers

Discovery of potent 2,4-difluoro-linker poly(ADPribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy

Poly (ADP-ribose) polymerase 1 (PARP1) is overexpressed in a variety of cancers, especially in breast and ovarian cancers; tumor cells that are deficient in breast cancer gene 1/2 (BRCA1/2) are highly sensitive to PARP1 inhibition. In this study, we identified a series of 2,4-difluorophenyl-linker analogs (15-55) derived from olaparib as novel PARP1 inhibitors. Four potent analogs 17, 43, 47, and 50 (IC50=2.2-4.4 nmol/L) effectively inhibited the proliferation of Chinese hamster lung fibroblast V-C8 cells (IC50=3.2-37.6 nmol/L) in vitro, and showed specificity toward BRCA-deficient cells (SI=40-510). The corresponding hydrochloride salts 56 and 57 (based on 43 and 47) were highly water soluble in pH=1.0 buffered salt solutions (1628.2 μg/mL, 2652.5 μg/mL). In a BRCA1-mutated xenograft model, oral administration of compound 56 (30 m?kg-1d-1, for 21 d) exhibited more prominent tumor growth inhibition (96.6%) compared with the same dose of olaparib (56.3%); in a BRCA2-mutated xenograft model, oral administration of analog 43 (10 m?kg-1d-1, for 28 d) significantly inhibited tumor growth (69.0%) and had no negative effects on the body weights. Additionally, compound 56 exhibited good oral bioavailability (F=32.2%), similar to that of olaparib (F=45.4%). Furthermore, the free base 43 of the hydrochloride salt 56 exhibited minimal hERG inhibition activity (IC50=6.64 μmol/L). Collectively, these data demonstrate that compound 56 may be an excellent drug candidate for the treatment of cancer, particularly BRCA-deficient tumors.

2. 4 - difluoro - 5 - (phthalazinone - 1 - methyl) - benzoyl piperazine compound and use thereof

The invention relates to a 2,4-difluoro-5-(phthalazone-1-methyl)-benzoyl piperazine compound and application of the 2,4-difluoro-5-(phthalazone-1-methyl)-benzoyl piperazine compound. Specifically, the invention discloses a compound of the structure shown in the formula I, wherein the definition of the compound of the structure shown in the formula I can be seen in the specification. The compound has the excellent PARP activity inhibitory effect and the excellent antitumor effect.

Optimization of potency and pharmacokinetics of tricyclic indole derived inhibitors of HCV NS5B polymerase. Identification of ester prodrugs with improved oral pharmacokinetics

HCV infections are the leading causes for hepatocellular carcinoma and liver transplantation in the United States. Recent advances in drug discovery have identified direct acting antivirals which have significantly improved cure rates in patients. Current

5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF

The present invention relates to 5,6-ring annulated indole derivatives of the formula (I), compositions comprising at least one 5,6-ring annulated indole derivatives, and methods of using the 5,6-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Tricyclic Indole Derivatives, compositions comprising at least one Tricyclic Indole Derivatives, and methods of using the Tricyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

2,3-SUBSTITUTED AZAINDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS

The present invention relates to 2,3-Substituted Azaindole Derivatives, compositions comprising at least one 2,3-Substituted Azaindole Derivatives, and methods of using the 2,3-Substituted Azaindole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS

The present invention relates to 4, 5 - ring annulated indole derivatives of formula ( I ), compositions comprising at leas t one 4, 5 - ring annulated indole derivatives, and methods of using the 4, 5 - ring annulated ^ndole derivatives for treating or preventing a viral inf ection or a virus - related disorder in a patient, (I) wherein ring Z of formula (I), is cyclohexyl, cyclohexenyl, 6-membered heterocycloalkyl, 6- membered heterocycloalkenyl, 6-membered aryl or 6-membered heteroaryl, wherein R1, R2, R3, R6. R7 and R10 are as described herein.

4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS

The present invention relates to 4,5-ring annulated indole derivatives, compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. Wherein ring Z, of formula (I), is a cyclopentyl, cyclopentenyl, 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl or 5-membered heteroaryl ring.